Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd is demonstrating strong growth potential driven by its advanced drug candidates, with recent revenue estimates for IMVT-1402 in Graves' Disease being favorably adjusted, indicating a positive trend in revenue forecasts. The company’s drug Brepocitinib has exhibited notable efficacy in rare diseases, particularly dermatomyositis (DM), which is supported by strong Phase 3 VALOR study results that show consistent effectiveness across various manifestations, enhancing investor confidence in its commercial prospects. Additionally, Batoclimab stands out as a unique clinical candidate with disease-modifying potential for Graves' disease, contributing to Roivant's advantageous position in a competitive market.

Bears say

Roivant Sciences Ltd faces challenges stemming from the disappointing outcomes of its clinical trials, particularly the failures of key assets like brepocitinib and IMVT candidates, which undermine the company’s developmental pipeline and prospects for growth. The negative sentiment is compounded by concerns surrounding the potential off-target effects of TSHR antagonism, which raises questions about the safety and efficacy of its drug candidates. Additionally, the reliance on chronic steroid therapies in treated conditions reflects a significant unmet medical need, emphasizing the difficulty Roivant may encounter in establishing competitive and effective treatment solutions in the market.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.